Link
- Argentinean Network of Women Living with HIV-AIDS
- Asia Pacific Network of People Living with HIV/AIDS
- bilaterals.org
- Cambodian People Living with HIV/AIDS Network (CPN+)
- Delhi Network of Positive People (DNP+)
- Essentialdrugs.org
- FACEBOOK PAGE: Stop the EU India Free Trade Agreement
- FTA Malaysia
- Health Action International – Asia Pacific
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS Unit
- MSF Access Campaign
- National Association of People Living with HIV and AIDS in Nepal (NAPN)
- Public Citizen
- Stop Peru FTA
- Thai Network of People Living with HIV/Aids (TNP+)
- Third World Network
Take Action
Archives
-
Recent Posts
- The Cost of Price: Why and How to Get Beyond Intellectual Property Internalism
- WHA 65 adopted the resolution for way forward on CEWG report on R&D
- Corporations Win Big in Battle Against Investment Regulation
- US and EU Derailing Ten-year Process to Create Health Research & Development Convention
- MSF: Update on debates at World Health Assembly on a possible R&D convention, 23 May 2012
Categories
Tag Archives: India
Minister-level meeting next month on India-EU free trade agreement
Source: Economic Times 20 May 2012 NEW DELHI: In a bid to fast track the much-delayed negotiations for the proposed free trade agreement between India and European Union, commerce minister Anand Sharma will hold comprehensive discussions with EU trade commissioner … Continue reading
India’s Generics-Big Pharma Battle Drops Drug Prices, Raises Legal Debate
Source: Intellectual Property Watch Patralekha Chatterjee 20 May 2012 The escalating battle between Big Pharma and India’s generic drug manufacturers is pushing down medicine prices in one of the world’s fastest growing pharmaceutical markets. German drug major Bayer AG is … Continue reading
Posted in Compulsory Licensing, Indian Patent Law, TRIPS flexibilities
Tagged Bayer, Cipla, India, Natco
Leave a comment
India objects to being put on US IPR watch list
Source: Economic Times 9 May 2012 NEW DELHI: India has protested being placed once again in the US priority watch list of countries with insufficient intellectual property protection and has said its regime is completely compliant with all WTO regulations, … Continue reading
Posted in Compulsory Licensing, Indian Patent Law, IPR Enforcement, TRIPS, TRIPS flexibilities
Tagged India, United States
Leave a comment
Compulsory licensing sets off a wave of price cuts in cancer drugs
Source: Livemint.com C.H. Unnikrishnan 8 May 2012 Mumbai: Prices of cancer medicines are dropping dramatically after India allowed Hyderabad’s Natco Pharma Ltd to sell a copy of German firm Bayer AG’s patented cancer drug Nexavar under compulsory licensing norms. … Continue reading
Posted in Compulsory Licensing, Indian Patent Law, TRIPS flexibilities
Tagged Bayer, Cipla, India, Natco, Novartis, Roche
Leave a comment
Sopaan STEP Cover Story: Spurious Medicine Scare – Are They Faking It?
The terms counterfeit and substandard medicines are often used interchangeably. Fake and substandard medicines both present serious concerns to public health, however, despite substandard medicines representing the larger problem of the two, most attention is paid to counterfeit medicines as … Continue reading
Posted in access to medicines, Anti-counterfeit law, IPR Enforcement, WHO
Tagged India
Leave a comment
Comments by Brook Baker: Bayer appeals against compulsory licence order
Source: Health GAP Professor Brook K. Baker 7 May 2012 Just as Novartis appealed from an order denying its patent application on Glivec, Bayer has now appealed the granting of a compulsory license on Nexavar, Rather than honestly state that … Continue reading
Posted in Compulsory Licensing, Indian Patent Law, R&D, TRIPS flexibilities
Tagged Bayer, India
Leave a comment
‘The current patent system is deeply flawed’
Source: Frontline V. VENKATESAN 21 April 2012 Interview with Shamnad Basheer, Intellectual Property Law Professor at NUJS. SHAMNAD BASHEER: “Drug companies have been reluctant to disclose their costs of drug discovery and development to the public.” PROFESSOR Shamnad Basheer joined … Continue reading
Posted in Compulsory Licensing, Indian Patent Law, IP Rights, Novartis Case, R&D, Sec 3 (d), TRIPS
Tagged Bayer, India, Novartis
Leave a comment
Question of efficacy
Source: Frontline LEENA MENGHANEY 21 April 2012 The country is clearly shaping its legislation to promote access to medicines by fostering generic production. INDIA’S approach to the revision of its Patents Act in 2005 is a clear example of … Continue reading
Western warnings
Source: Frontline R. RAMACHANDRAN 21 April 2012 India is coming under increasing pressure from the U.S. and the European Union for the strict patentability criteria it applies for medicines. RAJEEV BHATT Union Minister of Commerce and Industry Anand Sharma receives … Continue reading
A welcome first
Source: Frontline T.K. RAJALAKSHMI 21 April 2012 Industry reacts with caution to the grant of a compulsory licence to Natco, but cancer patients welcome it and hope for many more. VIVEK PRAKASH/REUTERS A cancer patient outside the Tata Memorial Hospital … Continue reading
Posted in Compulsory Licensing, Indian Patent Law, TRIPS flexibilities
Tagged Bayer, India, Natco, United States
Leave a comment
